| 2025 | 2024 | 2023 | 2022 | 2021 | 2018 | 2017 | 2016 | 2015 | 2013 | 2012 | 2011 | 2011 | 2010 | 2009 | 2008 | 2007 | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | 1,6 M € | +9.8% | 1,5 M € | -72.5% | 5,4 M € | +22.8% | 4,4 M € | — | — | — | — | — | ||||||||||||||
| Gross margin | 1,9 M € | -21.6% | 2,4 M € | -21.0% | 3,1 M € | +15.4% | 2,6 M € | +32.6% | 2,0 M € | +61.1% | 1,2 M € | +22.1% | 1,0 M € | +22.5% | 827,9 k € | — | — | — | — | 2,9 M € | +14.6% | 2,5 M € | +41.9% | 1,8 M € | +1.0% | 1,7 M € | +1.3% | 1,7 M € | ||||||
| EBITDA | 316,3 k € | -54.3% | 692,5 k € | -51.3% | 1,4 M € | +4.0% | 1,4 M € | +52.5% | 896,2 k € | +87.9% | 477,0 k € | +24.8% | 382,2 k € | +7.2% | 356,6 k € | +35.0% | 264,1 k € | +1112.6% | 21,8 k € | +107.6% | -288,3 k € | -140.6% | 710,4 k € | -4.7% | 745,8 k € | +44.2% | 517,1 k € | +49.3% | 346,4 k € | +16.2% | 298,1 k € | -9.2% | 328,3 k € | |
| Operating profit | 223,1 k € | -61.1% | 574,2 k € | -22.0% | 736,5 k € | -38.3% | 1,2 M € | +64.8% | 724,4 k € | +114.5% | 337,7 k € | +29.3% | 261,2 k € | +17.3% | 222,6 k € | +92.1% | 115,9 k € | +168.6% | -168,9 k € | +73.3% | -633,3 k € | -231.8% | 480,4 k € | +5.7% | 454,5 k € | +61.5% | 281,4 k € | +389.1% | 57,5 k € | +32.2% | 43,5 k € | -48.2% | 84,1 k € | |
| Profit/loss | 103,9 k € | -72.0% | 371,0 k € | -18.8% | 457,1 k € | -44.4% | 822,7 k € | +63.7% | 502,7 k € | +120.6% | 227,9 k € | +6.2% | 214,7 k € | +29.7% | 165,5 k € | +195.0% | 56,1 k € | +117.0% | -329,6 k € | -35.8% | -242,7 k € | -183.6% | 290,3 k € | +17.0% | 248,3 k € | +36.5% | 181,8 k € | +1711.2% | -11,3 k € | +73.2% | -42,1 k € | -290.7% | 22,1 k € | |
| Equity | 816,3 k € | 0.0% | 816,3 k € | 0.0% | 816,3 k € | 0.0% | 816,3 k € | 0.0% | 816,3 k € | +0.7% | 810,8 k € | +2.4% | 791,5 k € | +37.2% | 576,9 k € | +40.2% | 411,3 k € | -16.7% | 494,0 k € | +299.6% | 123,6 k € | -85.7% | 866,3 k € | +50.4% | 576,0 k € | +49.7% | 384,7 k € | +0.5% | 382,9 k € | -2.9% | 394,2 k € | -9.7% | 436,3 k € | |
| Total assets | 3,2 M € | -8.3% | 3,5 M € | -8.2% | 3,8 M € | -23.7% | 5,0 M € | +33.4% | 3,8 M € | +38.8% | 2,7 M € | +27.9% | 2,1 M € | -0.3% | 2,1 M € | +1.0% | 2,1 M € | -11.7% | 2,4 M € | -45.4% | 4,3 M € | +1.3% | 4,3 M € | +9.4% | 3,9 M € | +48.5% | 2,6 M € | +21.0% | 2,2 M € | -12.6% | 2,5 M € | +36.4% | 1,8 M € | |
| Cash | 677,2 k € | -19.9% | 845,3 k € | +66.4% | 507,9 k € | +93.2% | 262,9 k € | -10.7% | 294,3 k € | +291.9% | 75,1 k € | -56.7% | 173,4 k € | +19.7% | 144,8 k € | +53.2% | 94,5 k € | +289.9% | 24,2 k € | -86.1% | 174,3 k € | -52.6% | 367,6 k € | +158.4% | 142,3 k € | -48.5% | 276,5 k € | +149.1% | 111,0 k € | +44.5% | 76,8 k € | -4.5% | 80,4 k € | |
| Debts | 2,4 M € | -7.2% | 2,6 M € | -11.3% | 2,9 M € | -30.1% | 4,2 M € | +43.3% | 2,9 M € | +55.8% | 1,9 M € | +43.8% | 1,3 M € | -12.6% | 1,5 M € | -8.5% | 1,6 M € | -4.3% | 1,7 M € | -59.1% | 4,1 M € | +21.2% | 3,4 M € | +6.7% | 3,2 M € | +50.4% | 2,1 M € | +18.4% | 1,8 M € | -14.5% | 2,1 M € | +50.8% | 1,4 M € | |
| Staff | 20 | 22 | 22,7 | 19,9 | 19,1 | 11,7 | 9,2 | 6,6 | 5,7 | 14,2 | 57,5 | 35,7 | 48,3 | 48,2 | 36,3 | 36,2 | 36,9 | |||||||||||||||||
Public limited company · Brugge · incorporated on 09/09/1988 · 20,0 ETP
Public limited company profitable and well capitalised. Cash position declining (-19.9%).
Acceptable counterparty for a moderate engagement. Require 2 fiscal years of detailed accounts before any significant exposure. The abridged model hides revenue.
EUROFINS PHARMACEUTICAL PRODUCT TESTING BELGIUM is a Public limited company incorporated in 1988. Its main activity is: Technical testing and analysis. Its registered office is in Brugge. It employs on average 20,0 ETP workers (FTE).
Key indicators
7-day free trial, no credit card required.
7-day free trial, no credit card required.
7-day free trial, no credit card required.
Source: Belgian Official Gazette